Navigation Links
Simcere Pharmaceutical Group Invested Company Obtains Production License for H1N1 Flu Vaccine

NANJING, China, Sept. 22 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR) ("Simcere" or the "Company"), a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China, today announced that Jiangsu Yanshen Biological Technology Stock Co., Ltd ("Jiangsu Yanshen"), in which Simcere holds a 37.5% stake, was awarded a new drug certificate and production license from China's State Food and Drug Administration (SFDA) on September 18 for Jiangsu Yanshen's H1N1 vaccine. Of the eleven flu vaccine manufacturers in China, Jiangsu Yanshen is one of six currently licensed to produce the H1N1 vaccine.

"We are delighted that Jiangsu Yanshen has been awarded a new drug certificate and production license for the H1N1 flu vaccine," commented Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group. "Simcere's investment in Jiangsu Yanshen is an important part of our strategy to become a leader in China's fast growing biopharmaceutical industry."

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. These forward looking statements are based upon management's current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Further information regarding these and other risks is included in Simcere's filing with the U.S. Securities and Exchange Commission at . Simcere does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells anti-infective medication, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit .

SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
2. Simcere Pharmaceutical Group Reports Third Quarter 2007 Results
3. Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008
4. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results
5. Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.s Fourth Investor Tour of China
6. Simcere Pharmaceutical Group to Announce First Quarter 2008 Earnings on Tuesday, May 6, 2008
7. Simcere Pharmaceutical Group Acquires 70% Stake in Wuhu Zhong Ren Pharmaceutical Co. Ltd.
8. Simcere Pharmaceutical Group Announces SFDA Approval of First-to-Market Generic Biapenem Injection Anxin
9. Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results
10. Simcere Pharmaceutical Group to Participate in Goldman Sachs China Investment Frontier Conference 2008
11. Simcere Pharmaceutical Group Seeking Approval to Manufacture and Sell Influenza Drug zanamivir
Post Your Comments:
(Date:11/29/2015)... ... November 30, 2015 , ... ... new company, Sublime Beauty NATURALS®. All products are available on Amazon or its ... oils, organic facial serums and USDA Certified Organic Sesame Oil for Oil Pulling," ...
(Date:11/29/2015)... Orion, Clarkston, Metamora, Michigan (PRWEB) , ... November 29, 2015 , ... ... football games, basketball games. Things that as a Mother and Wife would love to ... was no mistake that I just happened to call Dr. Zaidan first. They have ...
(Date:11/29/2015)... ... November 29, 2015 , ... NewsWatch featured X-wing as ... available to consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted ... reality in the future. , It’s the future because flying cars are about to ...
(Date:11/29/2015)... ... ... While conventional walkers afford considerable help with mobility, their design does not ... inventor from Uniontown, Pa., has found a way to address those needs. , He ... walker to improve the user’s quality of life. To begin with, this improved mobility ...
(Date:11/29/2015)... Viejo, CA (PRWEB) , ... November 29, 2015 ... ... an all new and unique analog distortion effect tool designed specially for Final ... their footage, and create limiltess looks with the easy-to-use modification controls. Destoying and ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Belgium , Nov. 30, 2015   ... focused on developing blood-based diagnostic tests for a broad range ... will present at the LD Micro Conference, which will be ... CA. Attending from VolitionRx will be David ... Powell , Vice President of Investor Relations. ® ...
(Date:11/30/2015)... Israel , Nov. 30, 2015  OticPharma, ... acquiring and developing innovative therapies for ear, nose, and ... Keith A. Katkin as chairman of the company,s ... chief executive officer for OticPharma, Ltd.  "Keith brings a ... he will be able to share this experience and ...
(Date:11/29/2015)... Nov. 29, 2015   Royal Philips  (NYSE: PHG, ... solutions at the 2015 Radiological Society of North America ... McCormick Place in Chicago . Visitors ... the company,s broad portfolio of integrated Diagnostic Imaging, Clinical ... increase clinical performance, improve workflow and create a superior ...
Breaking Medicine Technology: